JFJames Walter Ferguson

James Walter Ferguson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Walter Ferguson has a total of 260 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study

    by Nasir Hussain, Rodrigo V. Motta, Usha Gungabissoon, Linda Casillas, Sumanta Mukherjee, Andrea Ribeiro, Megan M. Mclaughlin, Kaitlin Hagan, Khushpreet Bhandal, Penelope Rogers, et al.

    Background and Aims: Drug development in primary sclerosing cholangitis (PSC) is challenging, giving orphan disease status and variable rates of disease progression. A potential route for new therapies is through attenuation of symptoms. However, the epidemiology of symptomatic presentations and how they inherently fluctuate over time is not known. We conducted a prospective, multicenter study (trial registration: ISRCTN:15518794) to quantify the prevalence, intensity, and variability of pruritus in PSC. Approach and Results: Participants underwent face-to-face symptom assessment through the itch numerical rating scale (NRS) and 5D-itch tool. Clinical, radiological, and biochemical factors associated with pruritus intensity were determined, alongside the impact on health-related quality-of-life [EQ-5D-5L and chronic liver disease questionnaires (CLDQ)] over 12-week intervals (up to 48±4 weeks). In all, 220 patients participated, of whom n=116 reported pruritus, with n=56 scoring NRS worst itch ≥4. Median 5D-itch was greater in people with cirrhosis (11.0 vs. 8.0), transient elastography readings >8.0 kPa (9.5 vs. 5.0), and a history of ascending cholangitis (11.0 vs. 7.0) ( p <0.01; all). 5D-itch correlated positively with serum bilirubin, ALP, ALT, and AST; and negatively with CLDQ and EQ-5D-5L. In patients scoring NRS ≥4, 61.5% reported persistent pruritus intensity over 48 weeks. Reciprocally, 46.2% experienced a spontaneous ≥2 point reduction in NRS without the addition of a new anti-pruritic agent. Conclusions: One in 4 PSC patients experience moderate-severe pruritus, with greater symptom intensity in those with advanced disease. Our dataset is able to serve as a reference tool to aid future interventional study design, with regard to anti-pruritus therapies in PSC.


  • Open Access

    Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

    by Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, et al.

    Objective: Biochemical non‐response to ursodeoxycholic acid, as a first‐line therapy, is associated with a heightened risk of clinical events in primary biliary cholangitis (PBC). Herein, we determine whether biochemical non‐response to second‐line therapy in obeticholic acid (OCA) is also predictive of long‐term event‐free survival. Design: Data were collected from patients who initiated OCA at large, high‐volume centres in the UK, Italy, and Canada between August 2017 and 2019, with follow‐up continuing until June 2024. Biochemical non‐response was defined by POISE criteria. Clinical events were defined as hepatic decompensation, referral for transplantation, hepatocellular carcinoma, or death. Results: Our cohort consisted of 336 patients (29% with cirrhosis), of whom n = 150 (45%) discontinued OCA over 48 months. Over 851 patient‐years of OCA use, without the addition of another PBC therapy, n = 230, n = 192, n = 158 and n = 150 patients completed 12, 24, 36 and 48 months follow‐up, respectively. Of this cohort, 37%, 48%, 63% and 55% attained biochemical response, with 7%, 14%, 25% and 19% normalising ALP ( p < 0.01; all comparisons vs. baseline). Over 4 years, 64 patients experienced a clinical event. Twelve‐month biochemical non‐response associated with a heightened risk of clinical events (hazard ratio [HR]: 4.50; 95% CI: 1.74–20.23), as did cirrhosis (HR: 20.24, 10.15–40.32), hyperbilirubinaemia (HR: 2.55, 1.71–3.76), hypoalbuminaemia (HR: 0.92, 0.90–0.96) and thrombocytopenia (HR: 0.99, 0.98–0.99). The prognostic utility of biochemical non‐response (HR: 3.29, 1.72–14.96) and cirrhosis (HR: 19.67, 5.09–76.08) persisted on multivariable analyses. Conclusion: Biochemical response stratifies risk of clinical events in PBC patients under OCA treatment. Whilst response rates increase over time, discontinuation rates underscore the need for newer treatment paradigms.


  • Open Access

    Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial)

    by Dhiraj Tripathi, Kelly Handley, Lisa Holden, Zainab Abdali, Sue Jowett, Jonathan Mathers, Christopher Poyner, Paul Richardson, James Ferguson, Ian Rowe, et al.

    Background: The superior efficacy of non‐selective beta‐blockers (NSBB) compared with variceal band ligation (VBL) in the primary prevention of variceal bleeding is uncertain.Aim: To compare carvedilol versus VBL for primary prevention of variceal bleeding.Methods: CALIBRE was an investigator‐initiated, multicentre, randomised, controlled, open‐label trial. Participants were randomly assigned to 12.5 mg carvedilol once daily or VBL. Inclusion criteria were cirrhosis and medium to large oesophageal varices that had not bled. The primary outcome is any variceal bleeding within 1 year of randomisation. Secondary outcomes include survival, other complications of cirrhosis, quality of life, cost‐effectiveness and adverse events. Recruitment closed early, mainly due to the impact of the pandemic.Results: 265 participants (10% of the intended sample size) from 52 sites were randomised to carvedilol (n = 133) or VBL (n = 132) between 22 January 2019 and 31 August 2022. 5/133 participants (3.8%) in the carvedilol arm vs. 10/132 participants (7.6%) in the VBL arm experienced variceal bleeding (risk ratio 0.50 (95% confidence interval [CI]; 0.17–1.41); risk difference − 0.038 (95% CI; −0.094—0.017)). Serious adverse events occurred in one participant in each treatment arm, with no treatment‐related deaths. Of the secondary outcomes, there were no statistically significant differences. Carvedilol was cheaper and resulted in slightly more quality‐adjusted life years than VBL.Conclusions: The early terminated and, thus, underpowered CALIBRE trial showed no difference between carvedilol and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium‐to large‐sized oesophageal varices. No untoward safety concerns were noted.Trial Registration: ISRCTN73887615


  • Open Access

    The clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation: the LIFT prospective RCT

    by Julien Vionnet, Rosa Miquel, Juan G Abraldes, Juan-Jose Lozano, Pablo Ruiz, Miquel Navasa, Aileen Marshall, Frederik Nevens, William Gelson, Joanna Leithead, et al.

    Background: Long-term surviving liver transplant recipients can spontaneously develop operational tolerance, which allows them to completely discontinue their immunosuppression, but we lack validated tools to predict the likelihood of rejection following immunosuppression withdrawal. A previous clinical trial showed that a logistic regression algorithm including the transcript levels of a set of five genes in a liver biopsy could predict the success of immunosuppression withdrawal with high sensitivity and specificity. Objective: To determine if the use of a liver tissue transcriptional test of tolerance to stratify liver recipients prior to immunosuppression withdrawal accurately identifies operationally tolerant recipients and reduces the incidence of rejection, as compared with a control group in whom immunosuppression withdrawal is performed without stratification. Design and methods: Prospective, multicentric, phase IV, biomarker-strategy design trial with a randomised control group in which adult liver transplant recipients were randomised 1 : 1 to either: (1) non-biomarker-based immunosuppression weaning (Arm A); or (2) biomarker-based immunosuppression weaning (Arm B). Setting and participants: Adult liver transplant recipients ≥ 3 years post transplant (≥ 6 years if age ≤ 50 years old) with no history of autoimmunity or recent episodes of rejection, normal allograft function, and no significant histological abnormalities in a baseline screening liver biopsy, recruited from 12 transplant units in United Kingdom, Germany, Belgium and Spain. Intervention: Enrolled patients underwent a screening liver biopsy to exclude the presence of subclinical allograft damage. Eligible participants randomised to Arm A underwent gradual discontinuation of immunosuppression. Among participants allocated to Arm B, only those found to be biomarker-positive were offered immunosuppression withdrawal, while biomarker-negative participants remained on their baseline immunosuppression. Patients who completely discontinued immunosuppression and maintained stable allograft function underwent protocol liver biopsies at 12 and 24 months after immunosuppression withdrawal. Main outcome measure: Development of operational tolerance, defined as the successful discontinuation of immunosuppression with maintenance of normal allograft status 12 and 24 months after immunosuppression withdrawal. Results: One hundred and twenty-two patients were eligible to participate in the trial, 116 were randomised (58 to Arm A and 58 to Arm B), 80 initiated immunosuppression withdrawal and 34 were maintaining on their baseline immunosuppression. Among the 80 patients who initiated withdrawal, 54 (67.5%) developed clinically apparent rejection, 22 (27.5%) successfully discontinued immunosuppression, 21 underwent a liver biopsy and 13 (16.3%) met the histological criteria of operational tolerance at 12 months after immunosuppression discontinuation. The transcriptional tolerance biomarker was not accurate at identifying patients meeting the operational tolerance criteria [odds ratio 1.466, 95% confidence interval (CI) 0.326 to 9.215; p = 0.744; Sensitivity (Sn) 54%, Specificity (Sp) 42%, positive predictive value 16%, and negative predictive value 81%, with an accuracy of 44%]. Due to the poor diagnostic performance of the test, the trial was terminated prematurely following an interim analysis of the results. No patients lost their grafts as a result of rejection during the study duration. Conclusions: In selected liver transplant recipients, immunosuppression withdrawal proved to be feasible, but was successful in a much lower proportion of patients than originally estimated. A previously validated liver tissue transcriptional biomarker test was not considered accurate in predicting the success of immunosuppression withdrawal. Study registration: Current Controlled Trials ISRCTN47808000 and EudraCT 2014-004557-14. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 13/94/55) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 3. See the NIHR Funding and Awards website for further award information.


  • Open Access

    Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression

    by Julien Vionnet, Jorge Torres-Yaguana, Rosa Miquel, Juan G. Abraldes, Jurate Wall, Elisavet Kodela, Juan-Jose Lozano, Pablo Ruiz, Miguel Navasa, Aileen Marshall, et al.


  • UK guideline on the transition and management of childhood liver diseases in adulthood

    by Deepak Joshi, Jeremy Nayagam, Lisa Clay, Jenny Yerlett, Lee Claridge, Jemma Day, James Ferguson, Paul Mckie, Roshni Vara, Henry Pargeter, et al.

    Summary: Introduction: Improved outcomes of liver disease in childhood and young adulthood have resulted in an increasing number of young adults (YA) entering adult liver services. The adult hepatologist therefore requires a working knowledge in diseases that arise almost exclusively in children and their complications in adulthood.Aims: To provide adult hepatologists with succinct guidelines on aspects of transitional care in YA relevant to key disease aetiologies encountered in clinical practice.Methods: A systematic literature search was undertaken using the Pubmed, Medline, Web of Knowledge and Cochrane database from 1980 to 2023. MeSH search terms relating to liver diseases (‘cholestatic liver diseases’, ‘biliary atresia’, ‘metabolic’, ‘paediatric liver diseases’, ‘autoimmune liver diseases’), transition to adult care (‘transition services’, ‘young adult services’) and adolescent care were used. The quality of evidence and the grading of recommendations were appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.Results: These guidelines deal with the transition of YA and address key aetiologies for the adult hepatologist under the following headings: (1) Models and provision of care; (2) screening and management of mental health disorders; (3) aetiologies; (4) timing and role of liver transplantation; and (5) sexual health and fertility.Conclusions: These are the first nationally developed guidelines on the transition and management of childhood liver diseases in adulthood. They provide a framework upon which to base clinical care, which we envisage will lead to improved outcomes for YA with chronic liver disease.


  • Open Access

    Discarded livers tested by normothermic machine perfusion in the VITTAL trial: Secondary end points and 5-year outcomes

    by Hynek Mergental, Richard W. Laing, Amanda J. Kirkham, George Clarke, Yuri L. Boteon, Darren Barton, Desley A.H. Neil, John R. Isaac, Keith J. Roberts, Manuel Abradelo, et al.

    Normothermic machine perfusion (NMP) enables pretransplant assessment of high-risk donor livers. The VITTAL trial demonstrated that 71% of the currently discarded organs could be transplanted with 100% 90-day patient and graft survivals. Here, we report secondary end points and 5-year outcomes of this prospective, open-label, phase 2 adaptive single-arm study. The patient and graft survivals at 60 months were 82% and 72%, respectively. Four patients lost their graft due to nonanastomotic biliary strictures, one caused by hepatic artery thrombosis in a liver donated following brain death, and 3 in elderly livers donated after circulatory death (DCD), which all clinically manifested within 6 months after transplantation. There were no late graft losses for other reasons. All the 4 patients who died during the study follow-up had functioning grafts. Nonanastomotic biliary strictures developed in donated after circulatory death livers that failed to produce bile with pH >7.65 and bicarbonate levels >25 mmol/L. Histological assessment in these livers revealed high bile duct injury scores characterized by arterial medial necrosis. The quality of life at 6 months significantly improved in all but 4 patients suffering from nonanastomotic biliary strictures. This first report of long-term outcomes of high-risk livers assessed by normothermic machine perfusion demonstrated excellent 5-year survival without adverse effects in all organs functioning beyond 1 year (ClinicalTrials.gov number NCT02740608).


  • Open Access

    Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood

    by Suz Warner, Jeremy Rajanayagam, Emily Russell, Carla Lloyd, James Ferguson, Deirdre A. Kelly, Gideon M. Hirschfield


  • Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?

    by Jeremy S Nayagam, Steven Masson, James W Ferguson, William Griffiths, Deepak Joshi